Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024)

Maze Therapeutics (MAZE) reported Preferred Stock Liabilities of $508.1 million for Q4 2024, up 32.35% sequentially from $383.9 million in Q3 2024.

Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024) Analysis & Trends

Maze Therapeutics (MAZE) has 1 years of Preferred Stock Liabilities data on file, last reported at $508.1 million in Q4 2024.

For the quarter ending Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $508.1 million; the trailing twelve-month figure through Dec 2024 stood at $508.1 million (changed N/A YoY), and the FY2024 full-year result was $508.1 million, changed N/A from the prior year.
Preferred Stock Liabilities climbed to $508.1 million in Q4 2024, from $383.9 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $508.1 million in Q4 2024 to a low of $383.9 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Maze Therapeutics	1.49 Bn	1.49 Bn	18.21 Mn	-

Download Data